Antitubercular inhaled therapy: opportunities, progress and challenges.
about
Poly(D,L-lactide-co-glycolide) nanoparticle agglomerates as carriers in dry powder aerosol formulation of proteinsIntravascular detection of inflamed atherosclerotic plaques using a fluorescent photosensitizer targeted to the scavenger receptor.Application of nanotechnologies for improved immune response against infectious diseases in the developing worldExpression Profile of Markers of Apoptosis, Injury and Oxidative Stress in Human Lung Epithelium Cells-A5449 Receiving Chronic Exposure of Potential Anti-Tubercular Drug-trans-Cyclohexane-1, 4-Diamine Derivative-"9u".Synthesis, characterization, and in vivo efficacy of shell cross-linked nanoparticle formulations carrying silver antimicrobials as aerosolized therapeutics.An update on the use of rifapentine for tuberculosis therapy.Rifapentine-proliposomes for inhalation: in vitro and in vivo toxicity.Drug-resistant tuberculosis: emerging treatment options.Current development and future prospects in chemotherapy of tuberculosisThe potential advantages of nanoparticle drug delivery systems in chemotherapy of tuberculosis.Drug delivery systems: An updated reviewControlled-release approaches towards the chemotherapy of tuberculosis.Nanotechnology in the diagnosis and management of heart, lung and blood diseases.The nanoscale in pulmonary delivery. Part 2: formulation platforms.Ion-pair chromatography for simultaneous analysis of ethionamide and pyrazinamide from their porous microparticlesFighting tuberculosis: old drugs, new formulations.Nanotechnology-Based Approach in Tuberculosis Treatment.Consensus summary of aerosolized antimicrobial agents: application of guideline criteria. Insights from the Society of Infectious Diseases Pharmacists.Liposomes as drug delivery systems for the treatment of TB.Nanoparticle delivery of anti-tuberculosis chemotherapy as a potential mediator against drug-resistant tuberculosis.Has nanotechnology led to improved therapeutic outcomes?Novel formulation and drug delivery strategies for the treatment of pediatric poverty-related diseases.Natural carriers for application in tuberculosis treatment.State of the art and future directions in nanomedicine for tuberculosis.Nanoparticle-mediated pulmonary drug delivery: a reviewThe role of particle physico-chemical properties in pulmonary drug delivery for tuberculosis therapy.A review of emerging trends in the treatment of tuberculosis.Identifying the Interaction of Vancomycin With Novel pH-Responsive Lipids as Antibacterial Biomaterials Via Accelerated Molecular Dynamics and Binding Free Energy Calculations.The safety of ethambutol dihydrochloride dry powder formulations containing chitosan for the possibility of treating lung tuberculosis.Preparation of alginate-chitosan-cyclodextrin micro- and nanoparticles loaded with anti-tuberculosis compounds.Formation of concentric multilayers in a chitosan hydrogel inspired by Liesegang ring phenomena.Enhancement of apoptosis of THP-1 cells infected with Mycobacterium tuberculosis by inhalable microparticles and relevance to bactericidal activity.Toward an optimized treatment of intracellular bacterial infections: input of nanoparticulate drug delivery systems.Application of a four-fluid nozzle spray drier to prepare inhalable rifampicin-containing mannitol microparticles.Preparation and characterization of spray dried inhalable powders containing chitosan nanoparticles for pulmonary delivery of isoniazid.Numerical simulations of targeted delivery of magnetic drug aerosols in the human upper and central respiratory system: a validation study.Critical physicochemical and biological attributes of nanoemulsions for pulmonary delivery of rifampicin by nebulization technique in tuberculosis treatment.The Multirole of Liposomes in Therapy and Prevention of Infectious Diseases.Uptake of inhalable microparticles affects defence responses of macrophages infected with Mycobacterium tuberculosis H37Ra.Sustained release of isoniazid from polylactide microspheres prepared using solid/oil drug loading method for tuberculosis treatment.
P2860
Q30371205-7D82372C-B057-4DF5-8590-37AE05CC4D85Q33619336-7959F555-8DF1-46B9-8C76-9AA09EFE3AC6Q33894321-F429A1FF-A2BE-495C-8215-9ABFAA0CF584Q34221391-D57549C4-01E7-4D8A-B302-0CE817AE3120Q34873275-107BC9DA-DAAE-4793-A93B-DECB9E3B64BAQ35084363-96B3BEE6-6D4B-4D59-B26C-11A11A54C2BFQ35549569-CF852245-45E2-4906-A28F-07B66493EF55Q35683967-824283CC-F84C-4D30-9E23-610ABBF995D5Q35705874-E169EB63-3586-4AA8-807D-BD7BC326ED72Q36252799-3ED99E75-4921-4566-A134-B2F33251F2F8Q36300205-DC5E0440-C565-4038-9253-19A1253A16C7Q36321657-410A3D57-DA60-4947-9E6B-AD3B705CC435Q36748503-D2748827-1EF7-4840-A501-3D4FB1D15042Q36985898-0FAF3238-1CEA-4F26-90EB-D952A525226EQ37343494-7C4D89F7-1473-47E7-A11E-3C6A275014E9Q37579212-D45B1F4A-A42D-442C-9896-CBFB8AEB016CQ37624974-10698F53-B89B-4924-9040-3189B44FA99DQ37760514-59CF90A1-17EE-43A7-8959-EC9CA73B6B64Q37949386-ACA7D26E-A8C3-448B-9179-FEEBE7024674Q37969743-61093910-1FBF-462E-8025-6F09FA0499AFQ37970730-7CA55B8A-44F8-48CD-8825-646A6B97363DQ37976848-05108C6F-D92D-4698-BB91-E59A428282D1Q38044741-70C498B3-1FFB-428E-A4C6-EFD8D91D36F3Q38150371-B665BE3A-DCFC-410E-BECD-E8C633A40F12Q38203377-59C07A0A-C41B-4F4D-BF83-7C24562960A7Q38236719-4DC22736-0390-4DF8-8A0A-AE140651BB2BQ38264545-88D412D5-202D-414B-A6F2-74DC7C656F82Q38747718-54F40982-7937-4715-BD42-9383E2186FCAQ38932441-B3ABC163-E5C1-481B-8F5D-C363EB9E5972Q39203063-D9DE0D6A-AC2B-4598-8490-378E1D77140AQ39959461-FB08D003-5FD3-4F4A-A9E0-EC0E9AB068E9Q40100391-6163C16B-16A6-4A19-A2F8-D191827C386AQ40974806-277183FD-3DBE-4D92-A2F3-AB85D3B89A7DQ41989537-8E05C072-CE27-4A9C-8B98-B6DD9CA12883Q45223284-FC748BB3-DD84-4E97-8D87-C34E2D9EDA6BQ47195617-EDF32BAB-1A9A-4291-A9DE-7A4F0ECE1BAEQ50074735-2567F400-A891-4A89-A1F1-836BC82BA90DQ50124824-244ABC67-1672-4F06-B31F-4789B0E4A8AEQ51081845-478334E3-6E40-45E9-9848-411EE6A657D5Q51299384-BC5BF3D7-F295-4487-839B-407DA3744466
P2860
Antitubercular inhaled therapy: opportunities, progress and challenges.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
2005年论文
@zh
2005年论文
@zh-cn
name
Antitubercular inhaled therapy: opportunities, progress and challenges.
@ast
Antitubercular inhaled therapy: opportunities, progress and challenges.
@en
type
label
Antitubercular inhaled therapy: opportunities, progress and challenges.
@ast
Antitubercular inhaled therapy: opportunities, progress and challenges.
@en
prefLabel
Antitubercular inhaled therapy: opportunities, progress and challenges.
@ast
Antitubercular inhaled therapy: opportunities, progress and challenges.
@en
P2860
P356
P1476
Antitubercular inhaled therapy: opportunities, progress and challenges.
@en
P2093
G K Khuller
Rajesh Pandey
P2860
P304
P356
10.1093/JAC/DKI027
P407
P577
2005-03-10T00:00:00Z